Authors: Nikolaus Kohles Dorothea Nagel Dietrich Jüngst Petra Stieber Stefan Holdenrieder
Publish Date: 2012/09/11
Volume: 33, Issue: 6, Pages: 2401-2409
Abstract
Transarterial chemoembolization TACE therapy is an effective locoregional anticancer treatment for liver cancer patients Serum biomarkers involved in immunogenic cell death may be valuable for early predicting therapy response and estimating prognosis Sera of 50 prospectively and consecutively included hepatocellular carcinoma HCC patients undergoing TACE therapy were taken before and 24 h after TACE application In these samples soluble biomarkers involved in immunogenic cell death and among them highmobility group box 1 HMGB1 soluble receptor of advanced glycation end products sRAGE and DNase activity were measured They were compared with radiological response to therapy A total of 71 TACE therapies were evaluated of which 32 were classified as “no progression” and 39 as “progression” While HMGB1 levels increased already 24 h after TACE there was an early decrease of sRAGE and DNase activity Pretherapeutic and 24h values of sRAGE were significantly higher in the no progression group than those in the progression group There was no difference with respect to treatment response for DNase and HMGB1 Soluble RAGE is a new parameter with predictive relevance in primary liver cancer patients undergoing TACE therapyWe are very grateful for the committed support of Prof Jüngst who died recently We thank Dr Waggershauser from the Institute of Radiology of the University Hospital Munich for the excellent technical assistance in the evaluation of CT and MRI imaging
Keywords: